Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly EBITDA Margin came in at 82389.36% in Q1 2026, up 4798008.0% year-on-year from N/an in Q1 2025, and up 11.4% quarter-over-quarter from 92991.67% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBITDA Margin history runs 14 years deep, the most recent figure standing at 82389.36% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 4798008.0% year-over-year to 82389.36% in Q1 2026; TTM through Mar 2026 was 543.86%, a 11104719.0% increase from a year earlier, with the FY2025 full-year figure at 512.91%, up 9850530.0% from the prior year.
- EBITDA Margin grew to 82389.36% in Q1 2026 per VRDN's latest filing, from 92991.67% in the prior quarter.
- Across five years, EBITDA Margin topped out at 56.7% in Q3 2025 and bottomed at 142356.0% in Q2 2025.
- The 5-year median for EBITDA Margin is 82326.39% (2023), against an average of 73180.6%.
- Across the five-year window, EBITDA Margin sank 7077795 bps in 2023 and soared 9701307 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 46729.52% in 2022, then sank by 112 bps to 99275.0% in 2023, then slipped by 22 bps to 121488.89% in 2024, then advanced by 23 bps to 92991.67% in 2025, then advanced by 11 bps to 82389.36% in 2026.
- Per Business Quant, the three latest VRDN EBITDA Margin figures stand at 82389.36% (Q1 2026), 92991.67% (Q4 2025), and 56.7% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 631.55 Mn | 631.55 Mn | - | -82,389.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82,389.36% |
| Dec 31, 2025 | -92,991.67% |
| Sep 30, 2025 | -56.70% |
| Jun 30, 2025 | -142,356.00% |
| Mar 31, 2025 | -130,369.44% |
| Dec 31, 2024 | -121,488.89% |
| Sep 30, 2024 | -97,069.77% |
| Jun 30, 2024 | -100,259.72% |
| Mar 31, 2024 | -77,634.72% |
| Dec 31, 2023 | -99,275.00% |
| Sep 30, 2023 | -71,144.44% |
| Jun 30, 2023 | -82,326.39% |
| Mar 31, 2023 | -73,952.04% |
| Dec 31, 2022 | -46,729.52% |
| Sep 30, 2022 | -2,492.47% |
| Jun 30, 2022 | -11,548.44% |
| Mar 31, 2022 | -11,985.65% |
| Dec 31, 2021 | -13,589.25% |
| Sep 30, 2021 | -6,795.19% |
| Jun 30, 2021 | -1,651.19% |